The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Immunomedics; Sanofi
 
Bishoy Morris Faltas
Honoraria - Digital Science Press
Research Funding - Lilly
 
Elaine Tat Lam
Consulting or Advisory Role - Astellas Pharma; Calithera Biosciences
Research Funding - Advaxis (Inst); Argos Therapeutics (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Exelixis (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Constellation Pharmaceuticals
 
Philip James Saylor
No Relationships to Disclose
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Genentech; Novartis; Pfizer; Spectrum Pharmaceuticals
 
Julio Hajdenberg
Stock and Other Ownership Interests - Abbvie; Celator; Immunomedics
Honoraria - Abbvie; Incyte; Janssen Oncology; Novartis; Seattle Genetics/Astellas
Speakers' Bureau - Incyte; Janssen Oncology; Novartis; Seattle Genetics/Astellas
 
Alicia K. Morgans
Honoraria - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Genentech; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech; Sanofi
Research Funding - AstraZeneca; Bayer; Genentech; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Sanofi
 
Emerson A. Lim
No Relationships to Disclose
 
Kevin Kalinsky
Stock and Other Ownership Interests - Array BioPharma (I); Novartis (I)
Consulting or Advisory Role - Amgen; AstraZeneca; bioTheranostics; Eisai; Ipsen; Lilly; Novartis; pfizer
Speakers' Bureau - Lilly
 
Pamela S. Simpson
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Trishna Goswam
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
William A. Wegener
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Lilly; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi